Current therapies under investigation for COVID-19: potential COVID-19 treatments-Reference-Cited by-同舟云学术

Current therapies under investigation for COVID-19: potential COVID-19 treatments

Published:2020-08 Issue:8 Volume:98 Page:483-489
ISSN:0008-4212
Container-title:Canadian Journal of Physiology and Pharmacology
language:en
Short-container-title:Can. J. Physiol. Pharmacol.

Author:

Weisberg Ellen¹²,Sattler Martin¹²³,Yang Priscilla L.⁴⁵,Parent Alexander¹²,Gray Nathanael⁶,Griffin James D.¹²

Affiliation:

1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

2. Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.

3. Department of Surgery, Brigham and Women’s Hospital, MA 02115, USA.

4. Department of Cancer Cell Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

5. Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA.

6. Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.

Abstract

In response to the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), researchers are expeditiously searching for antiviral treatments able to alleviate the symptoms of infection, which can be life-threatening. Here, we provide a general overview of what is currently known about the structure and characteristic features of SARS-CoV-2, some of which could potentially be exploited for the purposes of antiviral therapy and vaccine development. This minireview also covers selected and noteworthy antiviral agents/supportive therapy out of hundreds of drugs that are being repurposed or tested as potential treatments for COVID-19, the disease caused by SARS-CoV-2.

Publisher

Canadian Science Publishing

Subject

Physiology (medical),Pharmacology,General Medicine,Physiology

Link

http://www.nrcresearchpress.com/doi/pdf/10.1139/cjpp-2020-0286

Reference93 articles.

1. Agostini, M.L., Andres, E.L., Sims, A.C., Graham, R.L., Sheahan, T.P., Lu, X. et al. 2018. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio, 9(2). 10.1128/mBio.00221-18.

2. Host Factors in Positive-Strand RNA Virus Genome Replication

3. Alattar, R., Ibrahim, T.B.H., Shaar, S.H., Abdalla, S., Shukri, K., Daghfal, J.N. et al. 2020. Tocilizumab for the Treatment of Severe COVID-19. J. Med. Virol. [Online ahead of print.] 10.1002/jmv.25964.

4. Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS Drugs

5. The biology and toxicology of molluscicides, bayluscide

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2;MedComm;2023-05-14

2. Gilteritinib: Repurposing of AXL‐targeting kinase inhibitors against COVID‐19;Journal of Medical Virology;2023-02-27

3. Therapeutic Effects of Cannabinoids and Their Applications in COVID-19 Treatment;Life;2022-12-15

4. Synthesis of Polylactic Acid Oligomers for Broad-Spectrum Antimicrobials;Polymers;2022-10-18

5. Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19;International Journal of Molecular Sciences;2021-02-17